Literature DB >> 17249202

In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization.

Bin Wu1, Wei-Jun Peng, Pei-Jun Wang, Ya-Jia Gu, Wen-Tao Li, Liang-Pin Zhou, Feng Tang, Guo-Ming Zhong.   

Abstract

OBJECTIVE: To investigate the value of in vivo proton magnetic resonance spectroscopy (MRS) in the assessment of hepatocellular carcinoma (HCC) and monitor its metabolic change shortly after transcatheter arterial chemoembolization (TACE).
METHODS: In this prospective study, 28 consecutive patients with large HCC (> or = 3 cm in diameter) confirmed by fine needle aspiration biopsy were recruited. The 1H MRS of all hepatic lesions and some uninvolved liver parenchyma were performed with 1. 5T whole body MR scanner. Among them, 15 cases were evaluated again about one week after TACE. The main metabolites such as choline and lipid before and after interventional therapy were measured to assess the early response of the tumor.
RESULTS: The technical success rate of 1H MRS in liver was high (33/41, 80%), closely related to breath motion, location of lesion, and size of voxel. In spectra, the choline compound peak of HCC elevated compared with uninvolved liver parenchyma. After TACE, both the amplitude and the area of choline resonance peak significantly descended (choline-to-lipid ratios from 0.352 +/- 0.080 to 0.167 +/- 0.030, P = 0.026; from 0.205 +/- 0.060 to 0.070 +/-0.020, P = 0.042, respectively); yet lipid resonance peak ascended.
CONCLUSIONS: In vivo 1H MRS is technically feasible for the evaluation of large focal hepatic lesions, however, the reproducibility and stability are not as good as routine MR scan. 1H MRS can monitor the early stage metabolic changes of HCC after TACE but limitation like quantification still exists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17249202

Source DB:  PubMed          Journal:  Chin Med Sci J        ISSN: 1001-9294


  5 in total

Review 1.  Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.

Authors:  Hee Kang; Ho Yun Lee; Kyung Soo Lee; Jae-Hun Kim
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

Review 2.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 3.  Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ke Yang; Xiao-Ming Zhang; Lin Yang; Hao Xu; Juan Peng
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

4.  Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy.

Authors:  Susanne Bonekamp; Jialin Shen; Nouha Salibi; Hong C Lai; Jeff Geschwind; Ihab R Kamel
Journal:  J Comput Assist Tomogr       Date:  2011 Mar-Apr       Impact factor: 1.826

5.  Evaluation of diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) as early response biomarkers in cervical cancer patients.

Authors:  Stefania Rizzo; Valentina Buscarino; Daniela Origgi; Paul Summers; Sara Raimondi; Roberta Lazzari; Fabio Landoni; Massimo Bellomi
Journal:  Radiol Med       Date:  2016-07-02       Impact factor: 3.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.